Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for Dopamine Receptor Upregulation in Methamphetamine Users
NCT03059563Phase 1Terminated
- Sponsor
- University of California, Los Angeles
- Start
- Jan 2018
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in stimulant use disorder (SUD) comparing Varenicline with Placebo (2 arms). Primary endpoint: Dopamine D2-type receptor availability at 21 days. Started Jan 2018; status: terminated.
02
Drugs
varenicline
03
Conditions
stimulant use disorder (SUD)
Beyond the preview
Go deeper on NCT03059563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059563.